Jonas Kroschke
German Cancer Research Center
10 Papers
Jonas Kroschke is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Potential of ChatGPT and GPT-4 for Data Mining of Free-Text CT Reports on Lung Cancer.
Mathias Fink,Arved Bischoff,Christoph A Fink,Martin Moll,Jonas Kroschke,Luca Dulz,Claus Peter Heußel,Hans-Ulrich Kauczor,Tim Frederik Weber +8 more
TL;DR: When using user-defined prompts, GPT-4 outperformed ChatGPT in extracting oncologic phenotypes from free-text CT reports on lung cancer and demonstrated better oncology reasoning with fewer confabulations.
116
Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry.
Ramon Lopez Perez,Ramon Lopez Perez,Franziska Münz,Jonas Kroschke,Jannek Brauer,Nils H. Nicolay,Peter E. Huber +6 more
TL;DR: The presented method enables a quantitative and longitudinal analysis of the DNA damage response after genotoxic stress, as induced by radiotherapy and a multitude of anti-cancer drugs, and can be widely applied as a comprehensive genotoxicity assay in many fields of oncology besides radio-oncology, including environmental risk factor assessment, drug screening and evaluation of genetic instability in tumor cells.
6
Quantitative CT analysis of lung parenchyma to improve malignancy risk estimation in incidental pulmonary nodules
Alan A. Peters,Oliver Weinheimer,Oyunbileg von Stackelberg,Jonas Kroschke,Lars Piskorski,Manuel Debic,Kai Schlamp,Linn Welzel,Moritz Pohl,Andreas Christe,Lukas Ebner,Hans-Ulrich Kauczor,Claus Peter Heussel,Mark O. Wielpütz +13 more
TL;DR: In this article , the authors evaluated the value of quantitative computed tomography (QCT) of the whole lung and nodule-bearing lobe regarding pulmonary nodule malignancy risk estimation.
Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring.
Jonas Kroschke,Oyunbileg von Stackelberg,Claus Peter Heussel,Mark O. Wielpütz,Hans-Ulrich Kauczor +4 more
TL;DR: Some NSCLC patients do not benefit from targeted therapies, and many patients suffer from tumor recurrence, pointing out the need for new biomarkers allowing for better tumor phenotyping and monitoring during treatment to assess patient outcome.
2